Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BCMA CAR-T + huCART19
- Development stage
- Phase 1
- Lead developer
- University of Pennsylvania
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
BCMA CAR-T + huCART19 is an investigational combination cellular immunotherapy developed by the University of Pennsylvania's Abramson Cancer Center. This autologous chimeric antigen receptor (CAR) T-cell therapy consists of two distinct products administered together: CART-BCMA, which targets B-cell maturation antigen (BCMA) primarily expressed on malignant plasma cells, and huCART19 (also known as CTL119), a humanized CAR-T product targeting the CD19 antigen. By simultaneously targeting BCMA and CD19, the therapy aims to provide a more comprehensive anti-tumor response and mitigate the risk of antigen escape in patients with multiple myeloma. The combination is currently being evaluated in Phase 1 clinical trials as a consolidation therapy for high-risk multiple myeloma patients responding to initial treatments, as well as for those with relapsed or refractory disease.
- Other names
- BCMA CAR-T + huCART19CART-BCMA + huCART19CART-BCMA with huCART19
02
Targets
BCMA (B-cell maturation antigen)CD19 (B lymphocyte antigen CD19)
Beyond the preview
Go deeper on BCMA CAR-T + huCART19.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BCMA CAR-T + huCART19.